Restoring our ubiquitination machinery to overcome resistance in cancer therapy.
作者信息
Li Xiaoling, Mu Ping
出版信息
Oncoscience. 2024 May 6;11:43-44. doi: 10.18632/oncoscience.600. eCollection 2024.
Abstract
摘要
相似文献
1
Restoring our ubiquitination machinery to overcome resistance in cancer therapy.
Oncoscience. 2024 May 6;11:43-44. doi: 10.18632/oncoscience.600. eCollection 2024.
2
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
Oncogene. 2024 Jan;43(4):265-280. doi: 10.1038/s41388-023-02890-5. Epub 2023 Nov 29.
3
UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3.
Oncogene. 2023 Feb;42(9):651-664. doi: 10.1038/s41388-022-02581-7. Epub 2022 Dec 26.
4
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment.
Future Med Chem. 2025 Jul 16:1-13. doi: 10.1080/17568919.2025.2533113.
5
The advancement of ubiquitination regulation in apoptosis, ferroptosis, autophagy, drug resistance and treatment of cancer.
Arch Biochem Biophys. 2025 Sep;771:110497. doi: 10.1016/j.abb.2025.110497. Epub 2025 Jun 9.
6
Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy.
Mol Cancer Ther. 2021 Mar;20(3):490-499. doi: 10.1158/1535-7163.MCT-20-0417. Epub 2020 Dec 4.
7
Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Oncogene. 2005 Apr 7;24(15):2474-82. doi: 10.1038/sj.onc.1208490.
8
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6.
9
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Oncogene. 2008 Dec 4;27(57):7201-11. doi: 10.1038/onc.2008.320. Epub 2008 Sep 15.
10
TBK1 is a signaling hub in coordinating stress-adaptive mechanisms in head and neck cancer progression.
Autophagy. 2025 Aug;21(8):1744-1766. doi: 10.1080/15548627.2025.2481661. Epub 2025 Apr 1.
引用本文的文献
1
PROTAC Technology as a New Tool for Modern Pharmacotherapy.
Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.
2
Androgen Deprivation-Induced TET2 Activation Fuels Prostate Cancer Progression via Epigenetic Priming and Slow-Cycling Cancer Cells.
bioRxiv. 2025 Mar 29:2025.03.26.645495. doi: 10.1101/2025.03.26.645495.
本文引用的文献
1
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
Cancer Discov. 2024 Aug 2;14(8):1496-1521. doi: 10.1158/2159-8290.CD-23-0539.
2
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
Oncogene. 2024 Jan;43(4):265-280. doi: 10.1038/s41388-023-02890-5. Epub 2023 Nov 29.
3
The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
Cancer Res. 2023 Sep 15;83(18):2990-2992. doi: 10.1158/0008-5472.CAN-23-2260.
4
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Cancer Cell. 2023 Aug 14;41(8):1427-1449.e12. doi: 10.1016/j.ccell.2023.06.010. Epub 2023 Jul 20.
5
UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3.
Oncogene. 2023 Feb;42(9):651-664. doi: 10.1038/s41388-022-02581-7. Epub 2022 Dec 26.
6
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Nat Cancer. 2022 Sep;3(9):1071-1087. doi: 10.1038/s43018-022-00431-9. Epub 2022 Sep 5.
7
The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer.
Clin Transl Med. 2022 Aug;12(8):e978. doi: 10.1002/ctm2.978.
8
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Cancer Cell Int. 2021 Apr 22;21(1):230. doi: 10.1186/s12935-021-01908-w.
9
Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview.
Endocr Relat Cancer. 2021 Feb;28(2):R31-R46. doi: 10.1530/ERC-20-0272.
10
A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo.
Neoplasia. 2020 Oct;22(10):522-532. doi: 10.1016/j.neo.2020.07.002.
Zotero 插件